As a novel multitarget receptor tyrosine kinase inhibitor that can inhibit tumor angiogenesis and proliferative signaling, anlotinib has been approved by only the China State Food and Drug Administration as a third-line treatment for RA-NSCLC in patients who have received ≥2 types of chemotherapy. This evidence concerns the gene NTRK1 and neoplasm.